Resources
7 Results (showing 1 - 7)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 5/17/2021 (updated 4/10/2024)
Medication-assisted treatment (MAT) is the use of medications, combined with counseling, to treat substance use disorders. Research has proven the effectiveness of MAT and addiction treatment experts endorse it, but a variety of barriers have prevented the widespread use of MAT. These include a lack of financing for medication, insufficient organizational infrastructure to deliver medication, state and county funding and regulatory obstacles, physician training and certification, staff and client resistance, and community attitudes.
Posted 4/21/2021 (updated 4/5/2024)
This News Brief defines psychostimulants; explains why psychostimulant use disorder is under-addressed, particularly in rural areas; reviews the reasons why people use psychostimulants and the harms they can cause; and addresses the impact of COVID-19 on psychostimulant use.
Posted 4/21/2021 (updated 4/5/2024)
This News Brief describes the need for harm reduction and treatment services in rural areas for people who use psychostimulants and how those services can be provided by the opioid treatment program
Posted 7/7/2021 (updated 4/2/2024)
This Technical Briefing provides a description of Peer-to-Peer Distribution of Naloxone (P2PN). This is based on six case studies of pioneers of P2PN; three from the UK and three international examples that inform the guidance in this Technical Briefing. This document will inform and be extended following a pilot of P2PN in four sites in England in 2019. These will be supported by small grants from EuroNPUD. The learning from this pilot will help test the model and peer education approach promoted in this briefing.
Posted 7/16/2020 (updated 3/28/2024)
The information in this document was guided by the vision of the U.S. Department of Health and Human Services’ Office on Women’s Health and lessons learned from a 3-year reentry enhancement project conducted across 3 different reentry organizations. The participating pilot sites were the Resonance Center for Women, Inc., the College and Community Fellowship, and the Institute for Health and Recovery . Using the information compiled through this project, this guide was created by the Substance Abuse and Mental Health Services Administration’s GAINS Center for Behavioral Health and Justice Transformation.
Posted 1/26/2024 (updated 3/28/2024)
On January 18, 2024, the Centers for Medicare & Medicaid Services (CMS) announced the Innovation in Behavioral Health (IBH) Model. IBH is focused on improving quality of care and behavioral and physical health outcomes for Medicaid and Medicare populations with moderate to severe mental health conditions and substance use disorder (SUD).
Posted 3/9/2022 (updated 3/27/2024)
A disproportionate number of people in jails have substance use disorders (SUDs).1 Incarceration provides a valuable opportunity for identifying SUD and addressing withdrawal.* Within the first few hours and days of detainment, individuals who have suddenly stopped using alcohol, opioids, or other drugs may experience withdrawal symptoms, particularly when they have used the substances heavily or long-term. Without its identification and timely subsequent medical attention, withdrawal can lead to serious injury or death. Deaths from withdrawal are preventable, and jail administrators have a pressing responsibility to establish and implement withdrawal policy and protocols that will save lives and ensure legal compliance. This brief describes the scope of the challenge, provides an overview of constitutional rights and key legislation related to substance use withdrawal, and outlines steps for creating a comprehensive response to SUD.